PEDIATRIC ONCOLOGY GROUP

这项提案代表了支持参与 儿科肿瘤组(POG)。本次合作研究致力于 急性白血病化疗方法的研究进展 儿童时期的其他肿瘤疾病。重大的姑息和 延长了生存时间，并做出了贡献 临床药理学专业。然而，这些研究的真正目的是 通过治疗根除肿瘤疾病。研究正在进行中 旨在反映不断增加的对肿瘤的攻击强度 手机。合作小组技术允许快速系列评估 在化疗中有希望的线索的合理大小。这些线索或新消息 方法通常是由工作组自己在#年的工作结果提出的 临床肿瘤学。因此，一份完整的议定书通常会提出新的 在新的议定书中探索的途径。此外，协议还包括 旨在最大限度地利用在临床或概念上取得的进展 实验动物和/或临床先导研究。分部 儿科血液学-肿瘤学 加州大学圣地亚哥分校(UCSD)参与了为期10年的 加入前与癌症和白血病B组的合作小组研究 1980年与儿科肿瘤学小组的部队。在1983年1月1日之间 到1984年12月31日，我们已经有26个小组的129名患者登记 礼仪研究。此外，私人情报局协调了一项第二阶段的研究 VP-16-213，并完成了关于治疗的小组议定书研究草案 早期霍奇金氏病的研究人员和其他加州大学圣地亚哥分校的研究人员 生殖细胞肿瘤、骨髓组织方案协调人 急性淋巴细胞白血病二次缓解或受累患者的移植 T细胞急性淋巴细胞白血病群组方案研究的实验室研究 神经母细胞瘤。我们计划继续积极参与所有阶段的工作 POG活动。

This proposal represents a request to support participation in the Pediatric Oncology Group (POG). This cooperative research is devoted to the investigation of chemotherapeutic approaches to acute leukemia and other neoplastic diseases of childhood. Significant palliation and prolongation of survival has been achieved and contributions have been made in clinical pharmacology. However, the real objective of these studies is the eradication of neoplastic diseases by treatment. Studies are being designed to reflect an increasing intensity of attack on the neoplastic cell. The cooperative group technique permits prompt evaluation in series of reasonable size of promising leads in chemotherapy. These leads or new approaches are often suggested by the results of the group's own work in clinical oncology. Thus, a completed protocol often suggests the new avenues to be explored in new protocols. In addition, protocols are designed to exploit maximal clinical or conceptual advances made in experimental animals and/or clinical pilot studies. The Division of Pediatric Hematology-Oncology in the Department of Pediatrics at the University of California, San Diego (UCSD) has a 10 year involvement in cooperative group studies with Cancer and Leukemia Group B prior to joining forces with the Pediatric Oncology Group in 1980. Between January 1, 1983 and December 31, 1984, we have had 129 patient registrations on 26 group protocol studies. In addition, the P.I. coordinated a Phase II study o n VP-16-213 and completed a draft on a Group Protocol study on the treatment of early stage Hodgkin's disease, and other UCSD investigators served as coordinators for Group Protocols on germ cell tumors, bone marrow transplantation for patients with ALL in second remission or involved in the laboratory investigation of Group Protocol studies in T-cell ALL or neuroblastoma. We plan to continue our active participation in all phases of POG activities.